Clinical Trials Browser

Not yet recruiting × Triple Negative Breast Neoplasms × 90 days × Clear all

NCT07478705 2026-03-17

EINSTEIN-TNBC

Phase NA Not yet recruiting

Recurrence, Triple Negative Breast Neoplasms

NCT07466303 2026-03-12

Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07458113 2026-03-09

BERLIN

Phase 2 Not yet recruiting

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT07458204 2026-03-09

EPPIL

Phase 2 Not yet recruiting

Recurrence, Triple Negative Breast Neoplasms

NCT07276880 2026-03-03

P-RAD(+)TN-DCT

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07441512 2026-03-02

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07272642 2026-02-25

DUNP19

Phase 1 Not yet recruiting

BreastGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT07423117 2026-02-20

A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy

Phase 1 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07419880 2026-02-19

RECLAIM

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT05741164 2026-02-17

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07217990 2026-02-17

NoCUT-BC

Phase 1/2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06224673 2026-02-13

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07297667 2026-02-13

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Phase 1 Not yet recruiting

BreastGenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

NCT07300475 2026-02-13

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Phase 1 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07407517 2026-02-12

POLARIS

Phase 3 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07340541 2026-02-09

EVOLVE-BDT

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07283692 2026-02-03

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07378306 2026-01-30

FACT-TN

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07357948 2026-01-22

WISH-OMICHIR

Phase NA Not yet recruiting

Triple Negative Breast Neoplasms

NCT07339176 2026-01-14

OP-NEU-101

Phase 1/2 Not yet recruiting

BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Phase 1 Not yet recruiting

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT07321015 2026-01-06

Fzp-MA-TNBC

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms